Asieris Pharmaceuticals (688176) was founded in March 2010 and is a global innovative drug company focused on urogenital tumors and other major disease areas. Upholding its corporate mission of "Improving human health and making life more dignified," Asieris Pharmaceuticals aspires to become an internationally leading pharmaceutical company integrating R&D, manufacturing, and commercialization in its focused therapeutic areas, providing integrated diagnosis and treatment solutions for patients in China and around the world. In March 2020, Efung Capital invested in Asieris Pharmaceuticals. In January 2022, Asieris Pharmaceuticals was listed on the STAR Market.